KATHLEEN K SCHOEMAKER
CIK 1207789 · last filed 2015-07-01
KATHLEEN K SCHOEMAKER is a corporate insider who has filed 58 SEC Form 4 insider transactions across 21 companies since 2007. The most recent filing, for GKOS, was dated Jul 1, 2015. Across all open-market trades the lifetime net is +$110.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $330.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$330.34M
21
58
$110.83M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GKOS | 10%+ Owner | 876,083 | $164.85 | $144.42M | $0 | 1 | 2015-07-01 |
| LIFE | 10%+ Owner | 958 | $20.11 | $19.3K | $0 | 1 | 2015-05-12 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | 10%+ Owner | 514,286 | $0.55 | $282.9K | $20.15M | 1 | 2014-08-07 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 33,890 | — | — | $0 | 1 | 2014-03-17 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 13,004 | $38.22 | $497.0K | $0 | 1 | 2014-02-04 |
| TNDM | 10%+ Owner | 318,906 | $18.39 | $5.86M | $0 | 1 | 2013-11-19 |
| VCYT | 10%+ Owner | 3,063,294 | $56.62 | $173.46M | $0 | 1 | 2013-11-04 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 5,250 | — | — | $0 | 1 | 2013-09-30 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 10%+ Owner | 513 | — | — | $3.00M | 1 | 2013-08-28 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 1,897,336 | — | — | $8.00M | 1 | 2013-07-16 |
| ESPR | 10%+ Owner | 2,066,935 | $3.18 | $6.57M | $4.00M | 1 | 2013-07-02 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 79,422 | $0.08 | $6.4K | $10.86M | 2 | 2013-06-05 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 88,011 | — | — | $13.44M | 6 | 2013-03-21 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 159,896 | — | — | $0 | 3 | 2013-01-18 |
| Durata Therapeutics, Inc. (DRTX) Delisted | 10%+ Owner | 22,306 | — | — | $7.06M | 1 | 2012-07-24 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 5,970 | — | — | $25.33M | 15 | 2011-12-22 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 21,156 | $26.68 | $564.4K | $16.40M | 2 | 2011-09-20 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 1,258 | $5.54 | $7.0K | $4.10M | 2 | 2011-06-03 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | 10%+ Owner | 3,115,960 | — | — | -$514.6K | 3 | 2009-01-30 |
| Volcano Corp (VOLC) Delisted | 10%+ Owner | 1,898,427 | — | — | -$985.0K | 8 | 2008-07-18 |
| SENORX INC (SENO) Delisted | 10%+ Owner | 24,665 | — | — | $0 | 1 | 2007-04-03 |
Recent Filings
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-07-01 | GKOS | Conv (C) | +6,132,581 | $0 | EDGAR |
| 2015-05-12 | LIFE | Conv (C) | +93,898 | $0 | EDGAR |
| 2014-08-07 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Mixed | +14,861,316 | $20.15M | EDGAR |
| 2014-03-21 | — | Disp (D) | −10,442,531 | -$146.20M | |
| 2014-03-17 | Achaogen, Inc. (AKAO) Delisted | Conv (C) | +2,020,939 | $0 | EDGAR |
| 2014-02-04 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Conv (C) | +1,765,711 | $0 | EDGAR |
| 2013-11-19 | TNDM | Mixed | +3,243,448 | $0 | EDGAR |
| 2013-11-04 | VCYT | Conv (C) | +3,086,024 | $0 | EDGAR |
| 2013-09-30 | Evoke Pharma Inc (OMED) Delisted | Conv (C) | +1,133,333 | $0 | EDGAR |
| 2013-08-28 | Tobira Therapeutics, Inc. (RGDO) Delisted | Mixed | +2,550,109 | $3.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.